Search - tctmd.com

Displaying 21 - 40 of 118

Sort: Relevancy | Date

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Daily News

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

Caitlin E. Cox

October 27, 2021

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

Advertisement

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

TCTMD’s Top 10 Most Popular Stories for January 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

What’s Going to Be Hot at ESC 2022?

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

PAD Patients Undertreated With Statins Despite Elevated CV Risk

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content